Heartland Advisors Inc. Lowers Stake in Haemonetics Co. (NYSE:HAE)

Heartland Advisors Inc. cut its position in Haemonetics Co. (NYSE:HAE) by 34.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 92,923 shares of the medical instruments supplier’s stock after selling 48,175 shares during the period. Heartland Advisors Inc. owned about 0.19% of Haemonetics worth $7,255,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently modified their holdings of HAE. Cerity Partners LLC raised its holdings in Haemonetics by 31.1% during the third quarter. Cerity Partners LLC now owns 8,855 shares of the medical instruments supplier’s stock valued at $712,000 after acquiring an additional 2,102 shares during the period. FMR LLC raised its stake in Haemonetics by 206.3% during the 3rd quarter. FMR LLC now owns 774,529 shares of the medical instruments supplier’s stock valued at $62,257,000 after purchasing an additional 521,640 shares during the period. BNP Paribas Financial Markets raised its stake in Haemonetics by 174.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 16,949 shares of the medical instruments supplier’s stock valued at $1,362,000 after purchasing an additional 10,774 shares during the period. Captrust Financial Advisors lifted its holdings in Haemonetics by 30.1% in the 3rd quarter. Captrust Financial Advisors now owns 4,248 shares of the medical instruments supplier’s stock worth $341,000 after purchasing an additional 982 shares in the last quarter. Finally, Paloma Partners Management Co bought a new position in Haemonetics in the 3rd quarter worth approximately $623,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on HAE. Bank of America lowered shares of Haemonetics from a “neutral” rating to an “underperform” rating and dropped their target price for the stock from $95.00 to $68.00 in a research report on Friday, February 7th. StockNews.com downgraded shares of Haemonetics from a “buy” rating to a “hold” rating in a report on Saturday, February 15th. Raymond James reiterated a “strong-buy” rating and issued a $115.00 target price (down from $120.00) on shares of Haemonetics in a research report on Friday, February 7th. JMP Securities dropped their price target on Haemonetics from $125.00 to $100.00 and set a “market outperform” rating for the company in a research note on Friday, February 7th. Finally, Barrington Research reduced their price objective on Haemonetics from $108.00 to $95.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Haemonetics presently has a consensus rating of “Moderate Buy” and an average price target of $101.22.

Haemonetics Stock Down 1.8 %

NYSE HAE opened at $63.03 on Friday. The company has a quick ratio of 2.55, a current ratio of 3.97 and a debt-to-equity ratio of 1.35. Haemonetics Co. has a 52 week low of $58.80 and a 52 week high of $97.97. The firm has a market capitalization of $3.17 billion, a price-to-earnings ratio of 24.81, a PEG ratio of 1.11 and a beta of 0.43. The company has a fifty day moving average of $66.05 and a two-hundred day moving average of $74.68.

Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. On average, analysts predict that Haemonetics Co. will post 4.55 earnings per share for the current year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.